- Report
- March 2024
- 196 Pages
Global
From €3243EUR$3,374USD£2,781GBP
€3603EUR$3,749USD£3,090GBP
- Report
- February 2024
- 100 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 106 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 176 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 120 Pages
Global
From €4565EUR$4,750USD£3,915GBP
From €5719EUR$5,950USD£4,904GBP
From €6247EUR$6,500USD£5,357GBP
- Report
- February 2024
- 150 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 80 Pages
Europe
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 181 Pages
Europe
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 90 Pages
United States
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 160 Pages
Middle East, Africa
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 90 Pages
Europe
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 70 Pages
Latin America
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 70 Pages
United States
From €4565EUR$4,750USD£3,915GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 85 Pages
North America
From €4565EUR$4,750USD£3,915GBP
- Report
- August 2023
- 150 Pages
North America
From €4565EUR$4,750USD£3,915GBP
Tresiba is a brand of long-acting insulin used to treat diabetes, a chronic endocrine and metabolic disorder. It is a basal insulin, meaning it is taken once or twice daily to provide a steady, low level of insulin throughout the day. It is used to control blood sugar levels in adults and children with type 1 and type 2 diabetes. It is also used to treat diabetic ketoacidosis, a serious complication of diabetes. Tresiba is available in both a pen and a vial form, and is taken in combination with other diabetes medications.
The Tresiba market is a competitive one, with several companies offering similar products. These include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Each company offers a range of long-acting insulin products, including Tresiba, to meet the needs of people with diabetes. Show Less Read more